Polimedica Centrum Badan Profilaktyki I Leczenia Sp. z o.o.
- Address
- Ul. Belgradzka 52/54, Ursynow, 02-793 Lodz, Poland
Cardiovascular Research
The centre is running a study on heart failure with mildly reduced or preserved ejection fraction and systemic inflammation, testing a new anti‑inflammatory agent.
- Evaluation of ziltivekimab as a once‑monthly subcutaneous injection
- Measurement of cardiovascular death and heart‑failure events as primary outcomes
- Integration with standard of care for HFmrEF/HFpEF patients
The trial aims to reduce serious cardiac events in patients whose heart function is compromised by inflammation, reflecting the site’s strength in cardiovascular disease research.
Respiratory Research
A parallel investigation focuses on asthma, comparing two single‑inhaler regimens to improve symptom control over a twelve‑month period.
- Comparison of Trimbow triple therapy versus Foster dual therapy
- Use of the Asthma Control Questionnaire‑5 to assess treatment effectiveness
- Emphasis on long‑term safety and patient‑reported outcomes
This study highlights Polimedica Centrum Badan Profilaktyki I Leczenia’s commitment to advancing respiratory care and offering better inhaled options for people living with asthma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Polimedica Centrum Badan Profilaktyki I Leczenia Sp. z o.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety and Tolerability of VRDN-003 in Patients with Thyroid Eye Disease: A Randomized, Double-Masked, Controlled Study | Viridian Therapeutics Inc. | Phase III | Not Recruiting | Jun 2025 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.